PHS
BMRN icon

PFM Health Sciences’s BioMarin Pharmaceuticals BMRN Stock Holding History

PFM Health Sciences’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-178,319
Closed -$9.8M – 75
2025
Q2 		$9.8M Buy
+178,319
New +$10.5M 0.83% 35
2023
Q4 		– Sell
-498,280
Closed -$44.1M – 68
2023
Q3 		$44.1M Buy
498,280
+147,982
+42% +$13.2M 2.08% 19
2023
Q2 		$30.4M Buy
350,298
+190,732
+120% +$17.9M 1.18% 38
2023
Q1 		$15.5M Sell
159,566
-150,835
-49% -$15.6M 0.69% 49
2022
Q4 		$32.1M Sell
310,401
-805,548
-72% -$75.6M 1.15% 39
2022
Q3 		$94.6M Buy
1,115,949
+276,578
+33% +$24.6M 3.42% 3
2022
Q2 		$69.6M Buy
839,371
+120,876
+17% +$9.62M 2.65% 11
2022
Q1 		$55.4M Buy
718,495
+253,555
+55% +$21.2M 2.07% 16
2021
Q4 		$41.1M Buy
+464,940
New +$38.4M 1.4% 37
2021
Q1 		– Sell
-314,499
Closed -$27.6M – 92
2020
Q4 		$27.6M Sell
314,499
-385,553
-55% -$30.6M 0.97% 41
2020
Q3 		$53.3M Buy
700,052
+216,973
+45% +$22M 2.46% 9
2020
Q2 		$59.6M Buy
483,079
+83,474
+21% +$8.3M 3.09% 6
2020
Q1 		$33.8M Sell
399,605
-154,029
-28% -$13.3M 2.77% 14
2019
Q4 		$46.8M Sell
553,634
-1,595,417
-74% -$121M 2.23% 17
2019
Q3 		$145M Buy
2,149,051
+69,663
+3% +$5.37M 4.28% 2
2019
Q2 		$178M Buy
+2,079,388
New +$178M 3.38% 3
2017
Q3 		– Sell
-153,018
Closed -$13.9M – 93
2017
Q2 		$13.9M Sell
153,018
-830,108
-84% -$75.5M 0.37% 69
2017
Q1 		$86.3M Sell
983,126
-74,433
-7% -$6.62M 2.16% 13
2016
Q4 		$87.6M Buy
1,057,559
+334,821
+46% +$28.8M 2.47% 7
2016
Q3 		$66.9M Buy
722,738
+151,634
+27% +$14.3M 1.96% 15
2016
Q2 		$44.4M Buy
+571,104
New +$48.6M 1.34% 34

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PFM Health Sciences's BMRN Position: Q3 2025 in Review

PFM Health Sciences sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 178,319 shares — an estimated $9.8M sold.

PFM Health Sciences first reported a position in BMRN in Q2 2016 and held it in 21 quarters. The position peaked at $178M in Q2 2019. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • PFM Health Sciences reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • PFM Health Sciences sold 178,319 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $9.8M.
  • PFM Health Sciences first reported a position in BioMarin Pharmaceuticals in Q2 2016 and held it in 21 quarters.
  • PFM Health Sciences's BioMarin Pharmaceuticals position peaked at $178M in Q2 2019.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on PFM Health Sciences's 13F filing for Q3 2025, filed 14 Nov 2025.